ArticleTranslational lung cancer research2026
A structural dose-response relationship between lymph node yield and survival after anatomical segmentectomy for early-stage NSCLC: a SEER-based retrospective cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adequate lymph node evaluation is central to oncologic segmentectomy for early-stage non-small cell lung cancer (NSCLC), yet the quantitative relationship between lymph node yield and survival remains unclear. This study aimed to evaluate the association between regional lymph node yield and overall survival after segmentectomy for early-stage NSCLC. Methods: Using Surveillance, Epidemiology, and End Results (SEER) (2000-2022), we identified patients with NSCLC undergoing anatomical segmentectomy and clinical N0M0 disease with tumors ≤30 mm. Regional lymph node yield ("regional nodes examined") was analyzed as 0, 1-5, 6-10, and >10 nodes, and continuously using restricted cubic splines. Overall survival (OS) was evaluated with Kaplan-Meier and multivariable Cox regression. Lung cancer-specific death was assessed using Fine-Gray competing-risk models. Results: A total of 2,217 patients met inclusion criteria (median follow-up 58 months), with 783 deaths during follow-up. OS differed significantly across lymph node yield groups (log-rank P<0.001). Five-year OS increased stepwise with higher yield, from 52.5% for 0 nodes to 65.9% for 1-5 nodes, 77.4% for 6-10 nodes, and 83.9% for >10 nodes. In multivariable Cox models, higher yields were independently associated with lower all-cause mortality: 1-5 nodes, hazard ratio (HR) =0.79 [95% confidence interval (CI): 0.67-0.94]; 6-10 nodes, HR =0.55 (95% CI: 0.44-0.70), and >10 nodes, HR =0.40 (95% CI: 0.30-0.52) (all P≤0.006; P for trend <0.001). Restricted cubic spline analysis supported a continuous association between yield and mortality risk without strong evidence of non-linearity (P overall <0.001; P non-linearity =0.27). The association was consistent across age (<70 Conclusions: In SEER patients undergoing anatomical segmentectomy for clinical N0M0 NSCLC ≤30 mm, higher regional lymph node yield demonstrated a dose-response association with higher OS and lower lung cancer-specific mortality. These findings support lymph node yield as a pragmatic marker of nodal evaluation during segmentectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.